Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.
Jorie Nicole McDonald leads editorial video efforts for Southern Living. Originally from Baton Rouge, Louisiana, she creates engaging visual content for the website and various social media platforms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback